LATEST NEWS
metastatic survey results
provided by the Advocacy Committee
In late 2023, Pheo Para Alliance launched a survey to gather information to develop a strategy to best support metastatic patients following the announcement regarding the cease of production of Azedra, the only FDA approved treatment for metastatic and unresectable pheochromocytoma and paraganglioma in late 2023. Fifty three clinicians from twenty-eight centers participated globally.
This survey was created as part of the Advocacy Committee.
